Poly(lactic-co-glycolic acid)-based growth factor gradient release microsphere stent as well as preparation method and application thereof

A technology of glycolic acid and growth factors, applied in medical science, prostheses, etc., can solve the problems of teratogenic incidence rate and lag in tissue engineering bone research, and achieve good gradient release performance, good cyst formation and film formation performance, and void space rate uniform effect

Active Publication Date: 2012-01-18
赵亮
View PDF4 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Embryonic stem cells (ESCs) are totipotent stem cells, which have unlimited proliferation and the ability to induce all cells from trophoblast to endoderm, mesoderm and ecto...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Poly(lactic-co-glycolic acid)-based growth factor gradient release microsphere stent as well as preparation method and application thereof
  • Poly(lactic-co-glycolic acid)-based growth factor gradient release microsphere stent as well as preparation method and application thereof
  • Poly(lactic-co-glycolic acid)-based growth factor gradient release microsphere stent as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] 1. Construction of homogeneous PLGA microspheres

[0039] PLGA microspheres with a diameter of 50 μm were prepared. PLGA composition (lactic acid: glycolic acid with a molar ratio of 1:1, molecular weight of the polymer ~25,000) was randomly polymerized to make PLGA, and PLGA was dissolved in dichloromethane DCM (DCM 30% W / V, mass-volume ratio) to form PLGA Dissolving solution, wherein the mass percentage of PLGA in the PLGA dissolving solution is 3%, the polymer solution controls the waveform generator through an ultrasonic sensor, passes through a small coaxial spray needle, produces homogeneous polymer droplets, and flows into a solution containing 0.5 % (mass percentage content) in the beaker of PVA, form PLGA polymer droplet. Early PLGA polymer droplets were stirred for 3-4 hours, then hardened to form microspheres, filtered and distilled water (~1L) was used to remove residual PVA. Finally, the PLGA polymer microspheres were freeze-dried for 48 hours, stored at ...

Embodiment 2

[0045] 1. Construction of homogeneous PLGA microspheres

[0046] PLGA microspheres with a diameter of 100 μm were prepared. The composition of PLGA (lactic acid: glycolic acid with a molar ratio of 1:0.3, the molecular weight of the polymer is ~25,000) was randomly polymerized to make PLGA, and the PLGA was dissolved with DCM (dichloromethane) (DCM 30% W / V, mass volume ratio) Form a PLGA solution, wherein the mass percentage of PLGA in the PLGA solution is 1%. The polymer solution controls the waveform generator through an ultrasonic sensor, and passes through a small coaxial nozzle to produce homogeneous polymer droplets, which flow into the In a beaker containing 0.8% (mass percent) PVA, PLGA polymer droplets were formed. Early PLGA polymer droplets were stirred for 3-4 hours, then hardened to form microspheres, filtered and distilled water (~1L) was used to remove residual PVA. Finally, the PLGA polymer microspheres were freeze-dried for 50 hours, stored at -20°C, and the...

Embodiment 3

[0052] 1. Construction of homogeneous PLGA microspheres

[0053] PLGA microspheres with a diameter of 150 μm were prepared. The composition of PLGA (lactic acid: glycolic acid with a molar ratio of 1:2, the molecular weight of the polymer ~25,000) was randomly polymerized to make PLGA, and the PLGA was dissolved with DCM (dichloromethane) (DCM 30%W / V, mass-volume ratio) The PLGA solution is formed, wherein the mass percentage of PLGA in the PLGA solution is 5%. The polymer solution controls the waveform generator through an ultrasonic sensor, and passes through a small coaxial nozzle to produce homogeneous polymer droplets, which flow into In a beaker containing 1.0% (mass percent) PVA, PLGA polymer droplets were formed. Early PLGA polymer droplets were stirred for 3-4 hours, then hardened to form microspheres, filtered and distilled water (~1L) was used to remove residual PVA. Finally, the PLGA polymer microspheres were freeze-dried for 45 hours, stored at -20°C, and the di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention provides a poly(lactic-co-glycolic acid)-based growth factor gradient release microsphere stent. The microsphere stent is prepared by a method comprising the following steps: firstly, preparing a poly(lactic-co-glycolic acid) (PLGA) homogeneous microsphere and a transforming growth factor (TGF)-beta3 and bone morphogenetic protein (BMP)-2/PLGA microsphere; dispersing the two microspheres into ddH2O to prepare suspension; injecting the suspension into a die with a filter device at the bottom; filtering by adopting the ddH2O, and regulating the position of the ddH2O in the die; accumulating the microspheres in the die; and sintering the microspheres by adopting absolute ethanol. According to the microsphere stent prepared in the invention, the original excellent biocompatibility of the PLGA is maintained, and the mechanical performance, osteochondral induction effect and seed cell carrying capability of the microsphere stent are remarkably improved. The microsphere stent has excellent biocompatibility, can carry an enough amount of seed cells, and is used for treatment of osteochondral defects caused by tumors, trauma, severe sepsis, congenital malformation and other various diseases.

Description

technical field [0001] The invention relates to an osteochondral biological repair composite material and its preparation method and application, in particular to a polylactic acid-glycolic acid copolymer-based growth factor gradient release microsphere scaffold and its preparation method and application. Background technique [0002] With the development of economic and social life, the incidence of osteochondral defects is increasing year by year. According to conservative estimates, about 7 million people in the United States visit a doctor for orthopedic diseases every year, and the medical cost is about 215 billion US dollars. There are also a large number of bone and joint diseases induced by various etiologies every year in my country, and the consumption is huge. Currently, joint prosthesis replacement is one of the effective treatment methods. But surgery to replace the joint is not only expensive, but also has the risk of complications. In recent years, the appli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61L27/22A61L27/18A61L27/54
Inventor 赵亮
Owner 赵亮
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap